Tammy Gomez compensation by year
Solventum Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $572,308 |
| Bonus | $0 |
| Stock awards | $3,838,274 |
| Option awards | $0 |
| Non-equity incentive | $504,547 |
| Pension and deferred compensation | $0 |
| All other | $42,238 |
| Total | $4,957,367 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Solventum Corp DEF 14A filed March 21, 2025, accession 0001964738-25-000038, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Solventum Corp filed document, accession 0001964738-25-000038. Every figure is read from that document and cited to the page and table it appears in. Filed March 21, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 44,346 | $2,929,497 | — |
| PSU | 23,758 | $1,569,453 | — |
| RSU | 13,026 | $872,852 | — |
| RSU | 11,879 | $784,727 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Solventum Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
13 Form 4 lines since the FY2024 proxy (filed March 21, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-13 | Exercise or conversion | — | 3,960 | $0.00 | 15,030 |
| 2026-05-13 | Tax withholding | — | 1,668 | $74.41 | 13,362 |
| 2026-05-13 | Exercise or conversion derivative | — | 3,960 | $0.00 | 3,960 |
| 2026-03-06 | Exercise or conversion | — | 3,300 | $0.00 | 11,965 |
| 2026-03-06 | Tax withholding | — | 895 | $69.41 | 11,070 |
| 2026-03-06 | Exercise or conversion derivative | — | 3,300 | $0.00 | 6,603 |
| 2026-03-05 | Grant or award derivative | — | 12,716 | $0.00 | 12,716 |
| 2026-01-02 | Exercise or conversion derivative | — | 4,342 | $0.00 | 4,342 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Solventum’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Bryan Hanson | Chief Executive Officer | $39,959,767 |
| Wayde McMillan | Chief Financial Officer | $10,321,753 |
| Christopher Barry | EVP and Group President, Medical Surgical | $9,763,527 |
| Amy Landucci | Chief Information & Digital Officer | $9,070,517 |
| Tammy Gomez · this page | Chief Human Resource Officer | $4,957,367 |
The full Solventum compensation record
free company briefThis page is one person within Solventum's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Solventum proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Solventum's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.